Meningitis Vaccine Uptake Plummets: Over One Million Teens Unprotected
New statistics have unveiled a dramatic and alarming decline in the uptake of the meningitis vaccine among teenagers across England. According to the latest data, more than one million adolescents have missed out on this crucial immunisation, a situation described by health experts as "terrifying" due to the potential public health consequences.
Steep Decline in Vaccination Rates
The MenACWY vaccine, which protects against four strains of meningitis (A, C, W, and Y), was introduced in 2015. Initially, it achieved an impressive uptake rate of 82.5 percent during its first full year of delivery in 2016/17. This vaccine is specifically offered to 14 and 15-year-olds through school-based programmes and has demonstrated high efficacy, reducing disease incidence by over 90 percent while fostering herd immunity nationwide.
However, recent figures from the UK Health Security Agency (UKHSA) indicate a significant downturn in vaccination rates. By 2025, the overall uptake had dropped to just 75 percent, leaving approximately 160,000 teenagers unprotected in that year alone. Cumulatively, this decline means that more than 1.07 million teens have now missed their vital doses, marking a stark reversal from the vaccine's early success.
Expert Warnings and Herd Immunity Concerns
Health professionals have expressed grave concerns over these statistics. Dr. Shamez Ladhani, a consultant epidemiologist at UKHSA, emphasised the ongoing importance of vaccination despite current low prevalence of the targeted strains. "While the number of cases of the four strains A, C, W and Y covered by the vaccine are currently very low, it is important that young people continue to take up the offer of vaccination," he stated. "The most recent figures show more than a quarter of year 10 pupils were unvaccinated, leaving many thousands of young people at risk."
Research from Oxford University in 2022 highlighted that vaccinating teenagers not only provides direct protection but also establishes herd immunity across all age groups. Professor Matthew Snape, formerly of the Oxford Vaccine Group, explained, "These studies report the results of throat swabs taken from over 24,000 teenagers in more than 170 secondary schools across the country... The results show us that by immunising teenagers with MenACWY vaccines we not only protect them directly, but also reduce the risk of all others in the community suffering from meningitis and sepsis due to these bacteria."
"Terrifying" Implications for Public Health
The decline in uptake has been met with particular alarm from clinicians who have witnessed the devastating effects of meningitis firsthand. Dr. Nelly Ninis, a consultant general paediatrician at Imperial College Healthcare NHS Trust, described the situation as "terrifying." She told The Times, "I've seen a lot of people die of meningococcal disease. This is a disease to be feared. Many healthcare professionals will buy the vaccine for their children when they go to university."
It is important to note that the MenACWY vaccine does not protect against meningitis B, the strain implicated in a recent outbreak in Kent that resulted in two fatalities and affected up to 34 individuals. Nonetheless, experts stress that the declining uptake for the four covered strains poses a significant and separate public health threat.
The UKHSA figures do not account for private vaccinations, and agency specialists note that the prevalence of the A, C, W, and Y strains has decreased substantially, partly due to the vaccine's initial success. However, the consensus among health authorities is clear: maintaining high vaccination rates among teenagers is essential to prevent a resurgence of these dangerous diseases and to sustain the protective benefits of herd immunity for the entire population.
